PMID- 31950647
OWN - NLM
STAT- MEDLINE
DCOM- 20210423
LR  - 20210423
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 5
DP  - 2020 Mar
TI  - Elevated eosinophil level predicted long time to next treatment in relapsed or 
      refractory myeloma patients treated with lenalidomide.
PG  - 1694-1702
LID - 10.1002/cam4.2828 [doi]
AB  - Lenalidomide is an immunomodulatory drug that is administered commonly in 
      patients with relapsed or refractory multiple myeloma (RRMM). Eosinophils have 
      immunological functions, for instance, in allergic diseases and asthma. The 
      purpose of this study was to investigate the clinical significance of elevated 
      eosinophil levels in patients with RRMM treated with lenalidomide. A total of 59 
      patients were included. Elevated eosinophil level was defined as an increase in 
      the eosinophil count of >/=250/microL from the eosinophil count on day 1 during the 
      first cycle. The percentage of patients with elevated eosinophil levels was 
      22.0%. The overall response ratio in the elevated eosinophil group and 
      nonelevated eosinophil group was 84.6% and 63.0% (P = .189), respectively. The 
      median time to next treatment (TTNT) in the elevated eosinophil group was 
      significantly longer than that in the nonelevated group (40.3 months vs 
      8.4 months; P = .017). Additionally, TTNT in the elevated eosinophil group with 
      partial response (PR) or better was significantly longer than that in the 
      nonelevated eosinophil group with PR or better (40.3 months vs 11.9 months; 
      P = .021). We concluded that elevated eosinophil levels were frequently observed 
      and might predict a longer TTNT in patients with RRMM treated with lenalidomide.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Suzuki, Kazuhito
AU  - Suzuki K
AUID- ORCID: 0000-0002-0300-378X
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University School of Medicine, Tokyo, Japan.
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan.
FAU - Nishiwaki, Kaichi
AU  - Nishiwaki K
AUID- ORCID: 0000-0003-2188-1241
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University School of Medicine, Tokyo, Japan.
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan.
FAU - Gunji, Tadahiro
AU  - Gunji T
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University School of Medicine, Tokyo, Japan.
FAU - Katori, Mitsuji
AU  - Katori M
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University School of Medicine, Tokyo, Japan.
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan.
FAU - Masuoka, Hidekazu
AU  - Masuoka H
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University School of Medicine, Tokyo, Japan.
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan.
FAU - Yano, Shingo
AU  - Yano S
AD  - Division of Clinical Oncology and Hematology, Department of Internal Medicine, 
      The Jikei University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200116
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - F0P408N6V4 (Lenalidomide)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Disease Progression
MH  - Drug Resistance, Neoplasm/immunology
MH  - Eosinophils/*immunology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lenalidomide/*administration & dosage
MH  - Leukocyte Count
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/blood/*drug therapy/immunology
MH  - Neoplasm Recurrence, Local/blood/*drug therapy/immunology
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Time Factors
MH  - Time-to-Treatment/*statistics & numerical data
PMC - PMC7050101
OTO - NOTNLM
OT  - chemotherapy
OT  - hematological cancer
OT  - immunology
EDAT- 2020/01/18 06:00
MHDA- 2021/04/24 06:00
PMCR- 2020/01/16
CRDT- 2020/01/18 06:00
PHST- 2019/10/28 00:00 [received]
PHST- 2019/12/17 00:00 [revised]
PHST- 2019/12/26 00:00 [accepted]
PHST- 2020/01/18 06:00 [pubmed]
PHST- 2021/04/24 06:00 [medline]
PHST- 2020/01/18 06:00 [entrez]
PHST- 2020/01/16 00:00 [pmc-release]
AID - CAM42828 [pii]
AID - 10.1002/cam4.2828 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Mar;9(5):1694-1702. doi: 10.1002/cam4.2828. Epub 2020 Jan 16.